GLP 1 Tracker - Tirzepatide
GLP 1 Tracker is a medical logging app for GLP-1 medication users on iOS and Android.
The App DNA
What makes this app unique?
It serves users who require a private, local-only record of injection sites, side effects, and health metrics to improve their medical appointment efficiency.
For Individuals managing weight loss or health journeys using GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound.
What does it look like?
Key features
Records date, time, dosage, and injection site for weekly regimens; drives weekly retention.
Logs physical symptoms for doctor discussions; increases switching costs.
Stores all health information locally on the device; acts as a privacy-first brand barrier.
How much does it cost?
The app operates as a free tool with no visible monetization gates, focusing on user acquisition within the medical category.
Velocity
Maintenance developmentperformanceopaqueShow more...
With only one release in the observed window and the latest update occurring 162 days ago, the development momentum is classified as maintenance. The latest release provided only generic bug fixes and performance improvements, offering no new features or content. There is no evidence of active development or live operations, and the long interval between updates suggests a focus on minimal stability maintenance rather than growth.
Who built it?
Hussain Mustafa
13+ apps tracked · Medical
GLP1 Shot Tracker - Bound
Pumping Tracker - Breast Milk
Bowel Movement & Poo Tracker
Glycemic Index Guide Tracker
Gestational Diabetes Tracker°
Invoice & Estimate Creator
Read Along Books For Kids: RR
Tinnitus Sound Therapy RngAway
Vehicle Maintenance Tracker
Reading Journey & Book Tracker
Pee Tracker & Bladder Log
Medication List & ReminderUser Sentiment
What do users think recently?
Recent user voice shows an excited sentiment. Users appreciate centralized tracking of medication doses and side effects helps patients communicate data to their healthcare providers and injection reminders and dose history logs keep users consistent with their prescribed medication schedules and regimens.
How are ratings & reviews evolving?
What users say, by theme
- Centralized tracking of medication doses and side effects helps patients communicate data to their healthcare providers
- Injection reminders and dose history logs keep users consistent with their prescribed medication schedules and regimens
- Clean interface design allows users to log medication doses and health metrics with minimal effort and time
- Paywall implementation immediately after installation frustrates users who expected a free or trial-based experience
28 of 28 recent reviews analyzed · moderate confidence · Excited overall
Read the full review analysisUnlock 2 more frustration themes and 3 user requests, each backed by review evidence.
Access the full report for freeCompetition
Competitive landscape for GLP 1 Tracker - Tirzepatide
How's the Medical market?
GLP 1 Tracker maintains a 4.75 rating across 212 total ratings, positioning it as a high-satisfaction utility in the medical category. The lack of recent feature updates contrasts with the active development cycles of rivals, signaling a risk of feature stagnation.
Read the market outlookThe rivals identified
By Runpoint LLC
Both applications target the same niche of GLP-1 medication users by providing specialized tracking for injection schedules and health metrics. They compete directly for users seeking to manage medication cycles and side effects without cost.
- Pokii provides visual injection site selection, reducing manual logging friction compared to standard text-based entry.
- Pokii includes medication level simulation, providing predictive data for injection planning that our app lacks.
Tracky: GLP-1 TrackerContender
Jabby: GLP-1 Shot TrackerContender
DoseFit: GLP-1 Tracker & DiaryContender
Gala GLP-1 TrackerContender
GLP AI: GLP-1 Tracker & CoachContender
GLPeak: GLP-1 Shot TrackerContender
ShotTrack - GLP-1 TrackerContender
Ozempic TrackerContender
Unlock the head-to-head verdict: where this rival wins, and where it loses.
Access the full report for freeThe Analyst's Read
Key takeaways for GLP 1 Tracker - Tirzepatide
Where is it heading?
Users report: The market for GLP-1 management is consolidating around automated, AI-assisted logging and wearable integration. GLP 1 Tracker remains stable due to its privacy-first model, but the lack of feature expansion leaves it exposed to rivals that offer more seamless data entry, which will erode its lead in user satisfaction if not addressed.
- The 4.75 rating indicates strong core utility for medication adherence, which keeps the user base stable despite the lack of updates.
- The immediate paywall implementation creates a churn risk, as users report feeling misled and uninstalling the app upon installation.
The SWOT
- Local-only storage creates a defensible privacy barrier
- Clean interface design sustains high user satisfaction
- Export functionality for medical reports would increase clinical utility
- Automated data syncing would reduce manual entry friction
Next best moves
Ship automated health platform syncing because it is the top-requested feature → reduce manual entry friction
+ 1 more prioritized moveThe counter-intuitive read
The privacy-first local storage is a liability, not a moat…
Read the full takeFeature gaps
Automated health platform syncing (available in GLPeak but absent here) +2
Since the last report: This report establishes the initial baseline for GLP 1 Tracker, identifying a maintenance-mode development cycle and significant user friction regarding an immediate paywall. The app currently lacks automated health data integration, creating a competitive gap against more advanced medical logging tools.
Bottom line
GLP 1 Tracker's privacy-first model retains core users, but the lack of automated data entry leaves it vulnerable to rivals. Prioritizing clinical data export and health platform syncing would address the primary friction points driving user churn.
Unlock 2 critical frictions, 2 market threats, 1 more prioritized move and the analyst’s take.
Access the full report for freeSources
- [1] App Store
Report last updated